TreeFrog Therapeutics, a France-based developer of stem cell-derived cell therapies, closed a $75 million Series B round. Bpifrance Large Venture led the funding, which included support from Leonard Green & Partners, Bristol Myers Squibb and XAnge. In addition to the funding, Frederic Desdouits was appointed as chief executive of the company. He was previously CEO of PCAS and managing director at Seqens CDMO. Laurent Higueret of Bpifrance Large Venture and Peter Zippelius of Leonard Green & Partners will join the TreeFrog board.
Recur, a Miami-based NFT platform, collected $50 million in Series A funding at a $333 million post-money valuation. Digital, a metaverse investment platform, led the round. Previous investors include Defi Alliance, Courtside VC, Volt Capital, Delphi Ventures and JST Capital.
Walking Fish Therapeutics Inc., a South San Francisco, Calif.-based startup that is developing B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease and recombinant antibody production, completed a $50 million Series A round led by investors including Emerson Collective, Illumina Ventures and Quan Capital.
Facebook says its rules apply to all. Company documents reveal a secret elite that's exempt.
Intuit agrees to buy Mailchimp for about $12 billion
Apple cyber flaw allows silent iPhone hack through iMessage
Fake Walmart news release spurs spike in little-used cryptocurrency litecoin
Buyout firms pump up investment in military technology
Around the Web
A new company with a wild mission: Bring back the woolly mammoth (New York Times)
Investors bet on the technologically unproven field of quantum computing (PitchBook)
(END) Dow Jones Newswires